NCT01730404View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
COPD
Interventions
DRUG

CHF6001 DPI

DRUG

Roflumilast

DRUG

Placebo

Trial Locations (5)

Unknown

Celerion, Belfast

Parexel, early phases, Harrow

Medicines Evaluation Unit Ltd, Manchester

Freeman Hospital, Newcastle

Nottingham University Hospitals NHS Trust, Nottingham

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT01730404 - Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients | Biotech Hunter | Biotech Hunter